Universal Influenza Vaccine Technology Landscape

The Landscape is a database of novel vaccine candidates designed to provide broader and more durable protection against circulating and pandemic influenza viruses, compared with current strain-specific seasonal influenza vaccines. CIDRAP is developing the landscape with support from the Global Funders Consortium for Universal Influenza Vaccine Development.

Tracker

Vaccine Candidates 106 Vaccine Candidates
Vaccine in clinical trials 21 Vaccines in Clinical Trials
Developers 99 Developers
Platforms 6 Platforms
Preclinical 85
Phase 1 11
Phase 2 7
Phase 3 3
Approved 0

Database

Previous Next
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Platform

Recombinant proteins

19
Vaccines in
Preclinical
3
Vaccines in
Phase 1
1
Vaccines in
Phase 2
1
Vaccines in
Phase 3
0
Vaccines in
Approved
Platform

Recombinant influenza virus-based

7
Vaccines in
Preclinical
2
Vaccines in
Phase 1
2
Vaccines in
Phase 2
0
Vaccines in
Phase 3
0
Vaccines in
Approved
Platform

Virus-vectored

13
Vaccines in
Preclinical
1
Vaccines in
Phase 1
3
Vaccines in
Phase 2
0
Vaccines in
Phase 3
0
Vaccines in
Approved
Platform

Virus-like particles (VLP)

16
Vaccines in
Preclinical
1
Vaccines in
Phase 1
0
Vaccines in
Phase 2
1
Vaccines in
Phase 3
0
Vaccines in
Approved
Platform

Non-VLP nanoparticles

17
Vaccines in
Preclinical
2
Vaccines in
Phase 1
1
Vaccines in
Phase 2
1
Vaccines in
Phase 3
0
Vaccines in
Approved
Platform

Nucleic acid-based

13
Vaccines in
Preclinical
2
Vaccines in
Phase 1
0
Vaccines in
Phase 2
0
Vaccines in
Phase 3
0
Vaccines in
Approved
Vaccine Name Sort descending Developer / Location Platform Phase Approach & Sources
3M2e-3HA2-NP chimeric protein Korea Research Institute of Bioscience and Biotechnology (Korea) Recombinant proteins Preclinical

Chimeric protein targeting M2e, HA and NP viral proteins; aimed at inducing influenza virus-specific antibody responses, cytotoxic T lymphocyte activity, and antibody-dependent cellular cytotoxicity.

3M2e-HA2-NP chimeric subunit Pasteur Institute of Iran (Iran) Recombinant proteins Preclinical

Recombinant chimeric protein 3M2e-HA2-NP containing conserved regions of M2e, HA, and NP derived from influenza A virus.

3M2e-NP-HBc VLP Beijing Institute of Microbiology and Epidemiology (China) Virus-like particles (VLP) Preclinical

Chimeric HBc particle construct using a recombinant M2 protein with 3 tandem copies of M2e (3M2e), nucleoprotein (NP) epitopes and hepatitis B virus core (HBc); administered with an oil-in-water SP01 adjuvant.

3M2e-rHF nanoparticle Chinese Academy of Sciences (China) Non-VLP nanoparticles Preclinical

Tandem copies of M2e (3M2e) displayed on ferritin nanoparticles (recombinant human heavy chain ferritin, rHF); intranasal administration; aimed at stimulating cross-protective immunity through M2e-specific IgG antibodies, T-cell immune responses, and mucosal secretory-IgA antibodies.

A/NP+M2-rAd Food and Drug Administration (US) Virus-vectored Preclinical

Replication-deficient recombinant adenovirus-5 (rAd) vectors expressing conserved antigens NP and M2.

AAV‐vectored HA or cHA Robert Koch Institute (Germany) Virus-vectored Preclinical

Adeno‐associated virus (AAV) vectors expressing influenza virus HA or chimeric HA; aimed at inducing broadly protective antibodies.

Ace-DEX microparticle University of North Carolina (US) Non-VLP nanoparticles Preclinical

M2e- and cyclic GMP-AMP (cGAMP)-encapsulated acetylated dextran (Ace-DEX) microparticles (MP); antigen-adjuvant combination is aimed at activation of humoral and cellular responses.

Ad5-InfA-HA/M2e and Ad5-InfB-HA Etubics (US) Virus-vectored Preclinical

Adenovirus-vectored (Ad5) constructs using conserved HA sequences (A or B) + M2 proteins

AdC68-CR9114 Fudan University (China) Virus-vectored Preclinical

Chimpanzee adenoviral vector, AdC68, expressing CR9114, a broadly neutralizing monoclonal antibody isolated form the peripheral blood mononuclear cells of healthy donors; CR9114 targets different types of influenza viruses.

AdC68M2e(3)-NP vector Wistar Institute (US) Virus-vectored Preclinical

Recombinant replication-defective chimpanzee adenovirus (AdC68) vector expressing chimeric fusion protein M2e(3)-NP.

AP-M2e/tri-stalk VLP Latvian Biomedical Research and Study Centre (Latvia) Virus-like particles (VLP) Preclinical

Panel of constructs based on HA tri-stalk and triple M2e (3M2e) antigens integrated into a bacteriophage AP205 VLP platform; aimed at broad protection against seasonal and novel influenza strains.

AuNP-M2e + sCpG nanoparticle Texas Tech University (US) Non-VLP nanoparticles Preclinical

Gold nanoparticle (AuNP) M2e vaccine with CpG as an adjuvant.

Bifluagen KJ Biosciences (US), Texas A&M University (US) Non-VLP nanoparticles Preclinical

Novel dual-domain nanoparticle fusion protein pres